Avalo Q3 net income $23M; first patient dosed in Phase 2 LOTUS trial for HS

Avalo Therapeutics, Inc.

2024-Q3 EPS reported -$22.63 revenue$249,000

Net income of $23.0M for Q3 2024 vs net loss of $5.2M in Q3 2023; diluted net loss per share $2.83.
Cash $81.9M at Sep 30, 2024; subsequent $58.1M warrant exercise proceeds extend runway into at least 2027.
First patient dosed in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa; topline data expected 2026.
R&D expenses $9.5M, up from $1.2M YoY due to AVTX-009 trial initiation and development costs.
Total revenues minimal at $249K; operating loss $12.9M for the quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.